1. Home
  2. ANL vs DEA Comparison

ANL vs DEA Comparison

Compare ANL & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$15.11

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Logo Easterly Government Properties Inc.

DEA

Easterly Government Properties Inc.

BUY

Current Price

$22.96

Market Cap

1.1B

Sector

Real Estate

ML Signal

BUY

Company Overview

Basic Information
Metric
ANL
DEA
Founded
2004
2011
Country
Singapore
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
1.1B
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
ANL
DEA
Price
$15.11
$22.96
Analyst Decision
Strong Buy
Hold
Analyst Count
7
7
Target Price
★ $29.50
$25.79
AVG Volume (30 Days)
143.5K
★ 439.8K
Earning Date
08-14-2026
10-26-2026
Dividend Yield
N/A
★ 7.69%
EPS Growth
N/A
★ 50.00
EPS
N/A
★ 0.08
Revenue
N/A
★ $336,099,000.00
Revenue This Year
$243.83
$7.51
Revenue Next Year
N/A
$2.65
P/E Ratio
★ N/A
$290.38
Revenue Growth
N/A
★ 11.27
52 Week Low
$0.88
$20.56
52 Week High
$17.25
$25.96

Technical Indicators

Market Signals
Indicator
ANL
DEA
Relative Strength Index (RSI) 50.08 35.98
Support Level $14.70 $22.70
Resistance Level $15.29 $24.40
Average True Range (ATR) 1.02 0.44
MACD -0.11 0.02
Stochastic Oscillator 29.50 31.23

Price Performance

Historical Comparison
ANL
DEA

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About DEA Easterly Government Properties Inc.

Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: